// App-Quantinova.ai

2462 : MondoA mediates in vivo aggressiveness of common ALL and may serve as a T-cell immunotherapy target

Researchers

Presenter

  • Alexandra Sipol

Principal Investigators

  • Thomas G. P. Grunewald

  • Juliane Schmaeh

  • David Schirmer

  • Monique L. den Boer

  • Rebeca Alba Rubio

  • Michaela Baldauf

  • Caroline Wernicke

  • Hans-Jochem Kolb

  • Martin Horstmann

  • Gunnar Cario

  • Guunther Richter

  • Stefan Burdach

Medical Centers

  • Children's Cancer Research Center, Department of Pediatrics, Technische Universitat Munchen, CCCM Munich - Comprehensive Cancer Center and German Translational Cancer Research Consortium (DKTK), Munich, Germany

  • Laboratory for Pediatric Sarcoma Biology, Institute of Pathology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany

  • Schleswig-Holstein University Medical Center, Kiel, Germany

  • Erasmus University Medical Center, Department of Pediatric Oncology, Rotterdam, Netherlands

  • Children's Cancer Research Institute and Department of Pediatric Hematology and Oncology, University of Hamburg Medical Center, Hamburg, Germany.

Locations

  • Germany

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved